.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,744,477

« Back to Dashboard

Details for Patent: 5,744,477

Title: Method for treatment of obesity using prolactin modulators and diet
Abstract:The present invention is directed to an improvement in a method of weight and/or body-fat reduction comprising a (preferably moderate) reduction in the caloric intake of a subject in need of such treatment in combination with administration to said subject of a prolactin inhibitor. Additionally, the present invention is directed to an improvement in a method for altering and/or resetting prolactin profiles (and thereby controlling one or more metabolic disorders such as obesity, excessive body fat, hyperlipidemia, hyperlipoproteinemia, hyperglycemia, hypercholesterolemia, hyperinsulinemia, insulin resistance, glucose intolerance, and Type II diabetes) comprising administration to a subject in need of such treatment of a prolactin inhibitor at a predetermined time or times during a 24-hour period in combination with a (preferably moderate) reduction of the caloric intake of said subject.
Inventor(s): Cincotta; Anthony H. (Andover, MA), Meier; Albert H. (Andover, MA)
Assignee: The Board of Supervisors of Louisiana State University and Agricultural (Baton Rouge, LA) Ergo Research Corporation (Walkefield, RI)
Filing Date:Jan 07, 1994
Application Number:08/178,569
Claims:1. A method for reducing weight in a patient in need of such treatment comprising in combination the steps of:

(a) administering daily to said patient a predetermined amount of a prolactin inhibitor confined to a first predetermined time; and

(b) restricting said patient's daily caloric intake.

2. The method as recited in claim 1 wherein said prolactin inhibitor comprises a dopamine agonist.

3. The method of claim 2 wherein said dopamine agonist is bromocriptine.

4. The method of claim 3 wherein said predetermined amount is within the range of 0.8 to 3.2 mg of bromocriptine.

5. The method of claim 1 wherein said prolactin administration and caloric intake restriction continue for a period of time from about 10 to about 180 days.

6. The method of claim 1 wherein said predetermined time is within the period from 0500 to 1300 hours.

7. The method of claim 1 wherein a second predetermined amount of a prolactin inhibitor is given to said patient at a second predetermined time wherein said second predetermined time is within the period from 0900 to 1300 hours and said first predetermined time is within the period from 0500 to 1000 hours.

8. The method of claim 1 wherein said restriction in caloric intake is moderate.

9. The method of claim 1 wherein the caloric intake of said patient after said restriction is from 70 to 90% of the number of calories required by said patient for weight maintenance.

10. The method of claim 9 wherein the caloric intake of said patient after said restriction is 70% of the number of calories required for weight maintenance, provided that the restricted caloric intake is not below 1200 calories per day.

11. The method of claim 1 wherein said reduction in body weight persists for an extended period of time after cessation of said treatment.

12. A method for reducing body fat in a patient in need of such treatment comprising in combination the steps of:

(a) administering daily to said patient a predetermined amount of a prolactin inhibitor confined to a first predetermined time; and

(b) restricting said patient's daily caloric intake.

13. The method as recited in claim 12 wherein said prolactin inhibitor comprises a dopamine agonist.

14. The method of claim 13 wherein said dopamine agonist is bromocriptine.

15. The method of claim 14 wherein said predetermined amount is within the range of 0.8 to 3.2 mg of bromocriptine.

16. The method of claim 12 wherein said prolactin administration and caloric intake restriction continue for a period of time from about 10 to about 180 days.

17. The method of claim 12 wherein said predetermined time is within the period from 0500 to 1300 hours.

18. The method of claim 12 wherein a second predetermined amount of a prolactin inhibitor is given to said patient at a second predetermined time wherein said second predetermined time is within the period from 0900 to 1300 hours and said first predetermined time is within the period from 0500 to 1000 hours.

19. The method of claim 12 wherein said restriction in caloric intake is moderate.

20. The method of claim 12 wherein the caloric intake of said patient after said restriction is from 70 to 90% of the number of calories required by said patient for weight maintenance.

21. The method of claim 20 wherein said caloric intake of the patient after said restriction is 70% of the number of calories required for weight maintenance, provided that the restricted caloric intake is not below 1200 calories per day.

22. The method of claim 12 wherein said reduction in body fat persists for an extended period of time after cessation of said treatment.

23. A method for increasing the efficiency of weight reduction in a patient in need of such treatment comprising in combination the steps of:

(a) administering daily to said patient a predetermined amount of a prolactin inhibitor confined to a first predetermined time; and

(b) restricting said patient's daily caloric intake;

said combination achieving an increased efficiency of weight reduction as compared to that achieved by either step (a) or step (b) alone: and thereby curbing or avoiding the metabolic rate decrease that accompanies dietary caloric restriction.

24. The method as recited in claim 23 wherein said prolactin inhibitor comprises a dopamine agonist.

25. A method for increasing body fat reduction in a patient in need of such treatment comprising in combination the steps of:

(a) administering daily to said patient a predetermined amount of a prolactin inhibitor confined to a first predetermined time; and

(b) restricting said patient's daily caloric intake;

said combination achieving an increased efficiency of body fat reduction as compared to that achieved by either step (a) or step (b) alone: and thereby curbing or avoiding loss of lean body mass that accompanies dietary caloric restriction.

26. The method as recited in claim 25 wherein said prolactin inhibitor comprises a dopamine agonist.

27. A method for reducing weight in a patient in need of such treatment comprising in combination the steps of:

(a) administering daily to said patient a predetermined amount of a prolactin inhibitor confined to a first predetermined time; and

(b) restricting said patient's daily caloric intake such that the caloric intake of said patient after said restriction is from 70 to 90% of said patient's daily caloric intake prior to restriction, provided that the restricted caloric intake is not below 1200 calories per day.

28. The method as recited in claim 27 wherein said prolactin inhibitor comprises a dopamine agonist.

29. The method as recited in claim 28 wherein said dopamine agonist is bromocriptine.

30. A method for reducing fat in a patient in need of such treatment comprising in combination the steps of:

(a) administering daily to said patient a predetermined amount of a prolactin inhibitor confined to a first predetermined time; and

(b) restricting said patient's daily caloric intake such that the caloric intake of said patient after said restriction is from 70 to 90% of said patient's daily caloric intake prior to restriction, provided that the restricted caloric intake is not below 1200 calories per day.

31. The method as recited in claim 30 wherein said prolactin inhibitor comprises a dopamine agonist.

32. The method as recited in claim 31 wherein said dopamine agonist is bromocriptine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc